hVIVO acquired CHIMagents in July 2021, further strengthening our capabilities in human challenge studies.

hVIVO is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge trials.

We provide end-to-end early clinical development services for our broad and long-standing client base of global biopharma companies.

For more information about our company and services:

Go to hVIVO

Stay connected

Sign up to our emails and follow us on social media to keep up to date with hVIVO.

By clicking Sign Up you're confirming that you agree with our Privacy Policy.
chevron-downarrow-up